BRCA1-deficient mammary tumor cells are dependent on EZH2 expression and sensitive to Polycomb Repressive Complex 2-inhibitor 3-deazaneplanocin A

INTRODUCTION: Treatment of breast cancer is becoming more individualized with the recognition of tumor subgroups that respond differently to available therapies. Breast cancer 1 gene (BRCA1)-deficient tumors are usually of the basal subtype and associated with poor survival rates, highlighting the n...

Descripción completa

Detalles Bibliográficos
Autores principales: Puppe, Julian, Drost, Rinske, Liu, Xiaoling, Joosse, Simon A, Evers, Bastiaan, Cornelissen-Steijger, Paulien, Nederlof, Petra, Yu, Qiang, Jonkers, Jos, van Lohuizen, Maarten, Pietersen, Alexandra M
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2009
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2750125/
https://www.ncbi.nlm.nih.gov/pubmed/19709408
http://dx.doi.org/10.1186/bcr2354

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2750125/
https://www.ncbi.nlm.nih.gov/pubmed/19709408
http://dx.doi.org/10.1186/bcr2354

Ejemplares similares